SummarySilicon Valley startup Orchid is pioneering embryo screening that sequences the full genome and assesses risk for diseases like cancer and bipolar disorder. Backed by tech elites, it promises healthier babies through data. While some hail it as revolutionary, others warn of ethical, scientific, and societal risks — including modern eugenics and inequality in access to such technology.